- 新型コロナウイルス
- 新型肺炎
- 韓国
- バイオシミラー
「セルトリオン」の写真・グラフィックス・映像
- 提供元
- 日付
- 種類
- 向き
- カテゴリ
- 色
- 提供元
- 日付
- 24時間以内 0
- 48時間以内 0
- 72時間以内 0
- 7日以内 0
- 30日以内 0
- 1年以内 0
- 期間を指定 12
- 日付指定なし 12
- 種類
- 写真 12
- グラフィックス 0
- 映像 0
- 向き
- 縦 4
- 横 8
- 正方形 0
- カテゴリ
- ニュース
- スポーツ
- エンターテインメント
- 教育向け
- カテゴリ指定なし
- 色
- カラー 12
- モノクロ 0
- 古い順
- 1
- 古い順
2020年12月29日Celltrion‘s COVID-19 drug under review Celltrion‘s COVID-19 drug under reviewCelltrion‘s COVID-19 drug under reviewThis file photo shows Celltrion Inc.‘s antibody treatment targeting COVID-19, disclosed on Dec. 22, 2020. On Dec. 29, the Ministry of Food and Drug Safety began a review of the treatment for approval. The South Korean company also started procedures to get approval for the drug‘s emergency use in the United States and Europe the same day. (Yonhap)/2020-12-29 16:51:29/＜Copyright ⓒ 1980-2020 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021010402147
2021年02月05日Final meeting on Celltrion‘s COVID-19 treatment Final meeting on Celltrion‘s COVID-19 treatmentFinal meeting on Celltrion‘s COVID-19 treatment Food and Drug Safety Minister Kim Gang-lip (R) speaks during a final meeting on the conditional approval of Celltrion Inc.‘s CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, at the ministry in Cheongju, North Chungcheong Province, on Feb. 5, 2021. (Yonhap)/2021-02-05 11:35:04/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021020801110
2021年02月05日Final meeting on Celltrion‘s COVID-19 treatment Final meeting on Celltrion‘s COVID-19 treatmentFinal meeting on Celltrion‘s COVID-19 treatment Oh Il-whan, head of the National Institute of Food and Drug Safety Evaluation, attends a final meeting on the conditional approval of Celltrion Inc.‘s CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, at the food and drug safety ministry in Cheongju, North Chungcheong Province, on Feb. 5, 2021. (Yonhap)/2021-02-05 11:35:22/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021020801043
2021年02月05日S. Korea OKs Celltrion‘s COVID-19 treatment for conditional use S. Korea OKs Celltrion‘s COVID-19 treatment for conditional useS. Korea OKs Celltrion‘s COVID-19 treatment for conditional use Food and Drug Safety Minister Kim Gang-lip speaks during a press conference at the ministry in Cheongju, North Chungcheong Province, central South Korea, on Feb. 5, 2021, on the conditional approval of pharmaceutical giant Celltrion Inc.‘s CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. (Yonhap)/2021-02-05 14:48:46/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021020808141
2021年02月08日Celltrion‘s COVID-19 treatment Celltrion‘s COVID-19 treatmentCelltrion‘s COVID-19 treatment Food and Drug Safety Minister Kim Gang-lip (R) views a sample of pharmaceutical giant Celltrion Inc.‘s COVID-19 antibody treatment, CT-P59, accompanied by the company‘s chief Seo Jung-jin, during his visit to a plant of the South Korean company in Incheon, west of Seoul, on Feb. 8, 2021. Celltrion‘s CT-P59 has won government approval on condition that it submits the results from its third clinical trial. (Yonhap)/2021-02-08 16:14:59/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021021004223
2021年02月08日Celltrion‘s COVID-19 treatment Celltrion‘s COVID-19 treatmentCelltrion‘s COVID-19 treatment This photo, taken Feb. 8, 2021, shows samples of pharmaceutical giant Celltrion Inc.‘s COVID-19 antibody treatment, CT-P59, which the company revealed at its plant in Incheon, west of Seoul. Celltrion‘s CT-P59 has won government approval on condition that it submits the results from its third clinical trial. (Yonhap)/2021-02-08 16:17:13/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021021004202
2021年02月09日Production line for Celltrion‘s COVID-19 treatment Production line for Celltrion‘s COVID-19 treatmentProduction line for Celltrion‘s COVID-19 treatment Workers look at bottles of pharmaceutical giant Celltrion Inc.‘s COVID-19 antibody treatment, CT-P59, on its production line at a plant of the South Korean company in Incheon, west of Seoul, on Feb. 9, 2021. (Yonhap)/2021-02-09 16:05:07/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021021013588
2021年02月09日Production line for Celltrion‘s COVID-19 treatment Production line for Celltrion‘s COVID-19 treatmentProduction line for Celltrion‘s COVID-19 treatment A worker views a bottle of pharmaceutical giant Celltrion Inc.‘s COVID-19 antibody treatment, CT-P59, on its production line at a plant of the South Korean company in Incheon, west of Seoul, on Feb. 9, 2021. (Yonhap)/2021-02-09 16:05:24/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021021013565
2021年02月17日Celltrion begins supplying COVID-19 antibody treatment Celltrion begins supplying COVID-19 antibody treatmentCelltrion begins supplying COVID-19 antibody treatment A medical worker views a bottle of a COVID-19 antibody treatment, manufactured by South Korean pharmaceutical giant Celltrion Inc., at Dongsan Hospital in Daegu, 302 kilometers southeast of Seoul, on Feb. 17, 2021. Celltrion began supplying medical institutions in the country the same day with the treatment, CT-P59, which has won the drug safety agency‘s conditional approval, becoming the first locally made treatment for COVID-19. (Yonhap)/2021-02-17 16:25:34/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021021803612
2021年11月11日Celltrion COVID-19 Antibody Treatment Receives EMA RecommendationNovember 11, 2021, Asuncion, Paraguay: Illustration: Logo of Celltrion Healthcare displayed on a smartphone in front of representation of medical syringe, ampoules and virus. Celltrion Group announced today that the European Medicine‘s Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59), a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe. (Credit Image: © Andre M. Chang/ZUMA Press Wire)、クレジット：©Ａｎｄｒｅ Ｍ． Ｃｈａｎｇ／ＺＵＭＡ Ｐｒｅｓｓ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2021111208266
2021年11月11日Celltrion COVID-19 Antibody Treatment Receives EMA RecommendationNovember 11, 2021, Asuncion, Paraguay: Illustration: Logo of Celltrion Healthcare displayed on a smartphone in front of representation of medical syringe, ampoules and virus. Celltrion Group announced today that the European Medicine‘s Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59), a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe. (Credit Image: © Andre M. Chang/ZUMA Press Wire)、クレジット：©Ａｎｄｒｅ Ｍ． Ｃｈａｎｇ／ＺＵＭＡ Ｐｒｅｓｓ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2021111208267
2021年11月11日Celltrion COVID-19 Antibody Treatment Receives EMA RecommendationNovember 11, 2021, Asuncion, Paraguay: Illustration: Logo of Celltrion Healthcare displayed on a smartphone in front of representation of medical syringe, ampoules and virus. Celltrion Group announced today that the European Medicine‘s Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59), a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe. (Credit Image: © Andre M. Chang/ZUMA Press Wire)、クレジット：©Ａｎｄｒｅ Ｍ． Ｃｈａｎｇ／ＺＵＭＡ Ｐｒｅｓｓ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2021111207174
- 1
